SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Gates Foundation

CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100

Reported Value
$126M
Q2 2023
Positions
9
Filings on Record
19
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Gates Foundation reported $126M in U.S.-listed holdings across 9 positions for Q2 2023.

The portfolio is heavily concentrated: VIR alone accounts for 30.4% of reported value.

The book was largely unchanged from Q1 2023.

Portfolio Metrics

Turnover
+2.3%
vs prior filed quarter
Largest Position
+30.4%
Vir Biotechnology

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $438MQ4 ’20Q1 ’21: $656MQ2 ’21: $692MQ2 ’21Q3 ’21: $342MQ4 ’21: $330MQ4 ’21Q1 ’22: $186MQ2 ’22: $130MQ2 ’22Q3 ’22: $127MQ4 ’22: $130MQ4 ’22Q1 ’23: $113MQ2 ’23: $126MQ2 ’23Q3 ’23: $84MQ4 ’23: $90MQ4 ’23Q1 ’24: $84MQ2 ’24: $60MQ2 ’24Q3 ’24: $44Mfilingsflow.com

Portfolio Composition

By security type
ADR: 47.8%Common Stock: 33.3%Other: 18.9%
  • ADR · 47.8% · $60M
  • Common Stock · 33.3% · $42M
  • Other · 18.9% · $24M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ATRECA INCTRIMMED74.8K931.8K$234,321$913,179
IMCRIMMUNCORE HLDGS PLCHELD+0576.9K+$6M$35M
CUREVAC N VHELD+01.63M+$6M$17M
BNTXBIONTECH SEHELD+0148.7K$2M$16M
VIRVIR BIOTECHNOLOGY INCHELD+01.56M+$2M$38M
EXSCIENTIAHELD+01.59M+$986,363$9M
BFLYBUTTERFLY NETWORK INCHELD+01.01M+$424,621$2M
LUMIRADX LTDHELD+014.29M+$142,857$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

9 positions
#IssuerClass% PortfolioValueShares
1VIRVIR BIOTECHNOLOGY INChistory →COM30.44%$38M1.56M
2IMCRIMMUNCORE HLDGS PLChistory →ADS27.53%$35M576.9K
3CUREVAC N VCOM13.48%$17M1.63M
4BNTXBIONTECH SEhistory →SPONSORED ADS12.77%$16M148.7K
5EXSCIENTIAADS7.50%$9M1.59M
6LUMIRADX LTDSHS5.46%$7M14.29M
7BFLYBUTTERFLY NETWORK INChistory →CL A COM1.85%$2M1.01M
8ATRECA INCCL A COM0.73%$913,179931.8K
9AMYRIS INCCOM NEW0.24%$301,170292.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$44M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$60M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$84M8May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$90M8Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$84M9Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$126M9Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$113M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$130M9Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M10Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$130M9Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$186M11May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$330M11Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$692M8Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$656M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$438M5Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.